Mirum Pharmaceuticals (MIRM) is a rare-disease pharma running three near-term FDA catalysts inside five months: zilurgisertib for FOP (PDUFA Sep 26, 2026), brelovitug Phase 3 topline for chronic HDV (H2 2026), and volixibat NDA submission for PSC (H2 2026). Up 150% YoY, RSI 76, 18% short interest, the stock has priced in a constructive catalyst run after a Q1 beat-and-raise. The Q1 2026 earnings call (May 6) was upbeat. The accompanying 10-Q was less so.

What the filing says

Buried in the 10-Q risk factor section (p.48): "while the NDA for zilurgisertib is supported by secondary endpoints, the pivotal study did not reach statistical significance on the primary endpoint. The FDA may determine that the clinical data for zilurgisertib is not sufficient to approve the NDA."

Management would not discuss PROGRESS data on the call, deferring to "an upcoming medical conference." The CFO stated $60M upfront in prepared remarks, then corrected to $16M in Q&A — the 10-Q confirms $16M plus up to $48M in regulatory milestones and $15M in commercial milestones. For an NDA-stage rare-disease asset, comparable deal economics run $50-200M+ upfront.

The Q1 commercial print was strong: net product sales $159.9M (+43% YoY), Livmarli $113.8M, Bile Acid Medicines $46.1M. FY26 guidance raised to $660-680M. Cash and short-term investments $420.6M. Cash contribution margin mid-50s%. But GAAP profitability slipped from 2027 → 2028 (operating-cash-flow-positive in 2027 maintained). R&D annualizing $391M with field force expanding 20 → 60 reps timed to 2027 approvals.

AZURE-1 Phase IIb (8-K Apr 27, 2026) met primary composite endpoint cleanly: 300mg QW arm 45% composite response vs 0% (p=0.003), zero Grade 3+ treatment-related AEs, zero discontinuations. Phase 3 topline expected H2 2026.

What the market thinks

PIPE pricing at $68.48 in January is the recent risk-on baseline; +63% since then on the AZURE-1 + VISTAS + Q1 catalyst run. Options on the Oct 16, 2026 expiry (covering the zilurgisertib PDUFA) trade at 74.7% ATM IV — IV rank 132% off the 52-week 23-62% range, term structure clearly concentrating event-vol around September. Liquidity is thin (161 OI), so implied probabilities are too noisy to extract cleanly. The directional read from the rally: the market is pricing the catalyst stack constructively — more so than the Phase 2b data and the zilurgisertib disclosure alone justify.

Sum-of-parts on probability-adjusted NPVs (commercial base at sector multiples + risk-adjusted volixibat and brelovitug NPVs + zilurgisertib NPV, net of debt and convert dilution) sits notably below the current quote. The gap is concentrated in how Phase 3 brelovitug success and zilurgisertib FDA approval are being weighted. The rally pattern is consistent with materially higher market-implied probability on both than our priors support.

Why the gap exists

Three reasons, each verifiable from public filings:

1. The primary-endpoint failure isn't synthesized with the deal economics. Incyte ran PROGRESS, filed the NDA on secondary endpoints, then divested worldwide commercialization rights to MIRM in April 2026 for $16M upfront. INCY went silent on zilurgisertib for five consecutive earnings calls (Q4 2024 through Q1 2026) and parallelly discontinued the molecule's myelofibrosis indication. INCY's FY25 10-K reduced the program to five lines with no NDA mention. Its Q1 2026 10-Q discloses the divestiture in a single sentence. Its Q1 2026 earnings call — six days after MIRM announced the deal — never mentions zilurgisertib. A strategic-fit explanation is available (Incyte's pipeline is oncology-weighted), but the parallel myelofibrosis discontinuation argues against fit-only — the molecule, not the indication, is what got de-prioritized. Tier-1 sophisticated originator handing regulatory risk to a small-cap acquirer at fire-sale economics is consistent with the originator pricing approval probability well below market.

2. The competitive sequencing isn't priced. Regeneron's garetosmab (anti-Activin A mAb for FOP) received BLA priority review acceptance on Feb 19, 2026, with target action date August 2026 — weeks before MIRM's September 26 PDUFA. Phase 3 OPTIMA showed 94%/90% heterotopic ossification reduction vs placebo (randomized double-blind). Industry base rates for priority-review BLAs with clean Phase 3 in orphan indications run 75-85% on-time approval. If garetosmab clears, the "no FDA-approved alternative" argument that drove Sohonos's 2023 totality-of-evidence path collapses for zilurgisertib. FDA faces approving a third FOP drug on secondary endpoints only, with a cleaner placebo-controlled mAb already on label.

3. The HDV cross-read isn't connected. Gilead's 10-K (Feb 24, 2026) discloses $590M total bulevirtide IPR&D impairment in 2025 ($190M Q2 + $400M Q4), citing "a potentially more competitive market." Bulevirtide remains in US CRL since Oct 2022 (manufacturing). The US HDV market is structurally open for a clean Phase 3 entrant. Market reads AZURE-1 Phase IIb as positive but hasn't tied it to Gilead's explicit acknowledgment of competitive displacement. This is the offsetting bull leg: MIRM's HDV optionality is plausibly more valuable, not less, than the consensus carries.

Risks (ranked by impact)

• AZURE Phase 3 hits cleanly: MIRM rallies 25-50% in H2 2026. Dominant variance event.
• PROGRESS secondary endpoints land strong: HO reduction >60% with mobility/functional wins lifts zilurgisertib approval probability materially.
• FDA grants AdCom with industry-friendly framing: Sohonos-class totality-of-evidence path opens for zilurgisertib.
• REGN garetosmab CRL or delay: Sequencing argument breaks; zilurgisertib retains "no alternative" tailwind.
• Convert note conversion en masse: $310M, 3.4x in the money, convertible at holder option in Q2 2026 — ≈16.5% potential dilution. Management has been silent despite redemption right since May 5, 2026.
• Bylvay continues outpacing Livmarli: Ipsen Q3 2025 Bylvay €135M already exceeds Livmarli Q3 2025 $92.2M. Caps the commercial bull case.

Catalysts

• Summer 2026: Zilurgisertib PROGRESS data at medical conference. ENDO 2026 (Jun 13-16), ASBMR 2026 (Sep), IFOPA-affiliated meetings.
• ~August 2026: REGN garetosmab PDUFA target action date.
• H2 2026: AZURE-1/AZURE-4 Phase 3 topline (likely Q3-Q4).
• September 26, 2026: MIRM zilurgisertib PDUFA.
• H2 2026: MIRM volixibat NDA submission for PSC.
• Q1 2027: VANTAGE Phase 2b (volixibat PBC) topline — slipped from Q4 2026.

What would change our mind

• PROGRESS data with HO reduction >60% AND mobility improvement in secondaries → zilurgisertib approval picture changes materially.
• FDA grants AdCom for zilurgisertib with public framing emphasizing rare-disease flexibility.
• REGN garetosmab CRL or delay beyond September 2026 → sequencing edge disappears.
• AZURE-1/AZURE-4 Phase 3 interim DSMB futility signal → entire long thesis breaks.
• INCY 8-K disclosing contingent-return optionality or milestone-trigger structure not in original deal docs → counterparty-pricing read weakens.

On structure

The bear case is specifically on the zilurgisertib leg. The dominant variance event (AZURE Phase 3) runs the opposite direction at 60-65% expected probability of success. Single-name exposure carries all three catalysts undifferentiated — the zilurgisertib bear payoff runs against the AZURE bull variance in the same instrument. A structure that isolates the zilurgisertib leg would require pairing against a position that neutralizes XBI exposure — REGN, with garetosmab as the conditioning catalyst, is a natural complement; an XBI hedge is another. At stretched tape, 18% short interest, with the convex zilurgisertib leg unresolved, single-name exposure at current levels concentrates the asymmetry unfavorably.

Memo LR: 0.8 — modestly bearish on the consensus zilurgisertib approval pricing, with the broader MIRM picture mixed.

Evidence